Hearts Preserved in Somah at Sub-normothermia Demonstrate Rapid Functional Restoration and Are Less Likely To Develop Heart Failure Upon Transplantation

2014 ◽  
Vol 33 (4) ◽  
pp. S176 ◽  
Author(s):  
S.K. Lowalekar ◽  
H. Cao ◽  
X. Lu ◽  
P.R. Treanor ◽  
H.S. Thatte
Author(s):  
Sharon Cresci ◽  
Naveen L. Pereira ◽  
Ferhaan Ahmad ◽  
Mirnela Byku ◽  
Lisa de las Fuentes ◽  
...  

One of 5 people will develop heart failure over his or her lifetime. Early diagnosis and better understanding of the pathophysiology of this disease are critical to optimal treatment. The “omics”—genomics, pharmacogenomics, epigenomics, proteomics, metabolomics, and microbiomics— of heart failure represent rapidly expanding fields of science that have, to date, not been integrated into a single body of work. The goals of this statement are to provide a comprehensive overview of the current state of these omics as they relate to the development and progression of heart failure and to consider the current and potential future applications of these data for precision medicine with respect to prevention, diagnosis, and therapy.


Neurosurgery ◽  
1983 ◽  
Vol 13 (2) ◽  
pp. 129-135 ◽  
Author(s):  
Leland A. Albright ◽  
Richard E. Latchaw ◽  
Robert A. Price

Abstract A 23-month-old infant with an extensive dural arteriovenous malformation (AVM) developed a heart murmur and cardiomegaly. The AVM involved the occipital and suboccipital dura mater and the tentorium, bilaterally. We embolized the AVM with Gelfoam and polyvinyl alcohol particulates, subtotally resected it, and embolized residual vessels with isobutyl cyanoacrylate, In spite of this extensive therapy, the malformation was not totally eradicated and an occipital pial AVM developed. This infant and the eight infants with posterior dural AVMs reported previously emphasize the difficulty of eradicating these lesions in infancy. We contrast the clinical features and therapy of infants and adults with posterior dural AVMs. Infants develop heart failure and cranial bruits beacause of arteriovenous shunts, whereas adults complain of headache and intracranial bruits. Infants need therapy to prevent progressive heart failure, intracranial hypertension, and perhaps cerebral ischemia. Ligation of arterial tributaries is inadequate therapy for these lesions. Embolization and resection of the malformation, when feasible, offers the best chance of curing posterior dural AVMs with extensive arterial tributaries.


PLoS ONE ◽  
2020 ◽  
Vol 15 (2) ◽  
pp. e0228860
Author(s):  
Amanda Martins Matias ◽  
Priscila Murucci Coelho ◽  
Vinícius Bermond Marques ◽  
Leonardo dos Santos ◽  
Aricia Leone Evangelista Monteiro de Assis ◽  
...  

Author(s):  
Ioannis Patrikios ◽  
Ioannis Patrikios ◽  
Mohammadali Badri

Cardiac sympathetic afferent that signal the sensation of cardiac pain, ostensibly, has more underlying mechanisms than what scientists have ever been led to believe. Cardiac sympathetic afferent reflex, also known as (CSAR), has been shown to be responsive to a variety of stimuli. Many of which scientists observed in increased levels during ischemia hydrogen ion, oxygen radicals, potassium, lactate, ATP, prostaglandins bradykinin, substance p and, finally and most importantly, endogenous substances (neurohormones) such as norepinephrine (NE). In the outset of chronic heart failure (HF), it has been known for a long time, that there are abnormalities in arterial baroreceptor input which depress its sensitivity, and arterial chemoreceptors seem augmented. Therefore, they tend to not only initiate sympathetic outflow but also to sensitise cardiac afferents which are appearing to do the same thing where there are abnormalities in vagus mechano-reflexes as well. Some of these receptors are in the spinal reticulate tract and interestingly these a third pathways give off neurons to the brainstem some in the hypothalamus and trance translate through the thalamus and then ultimately up into the cortex where we have sensation of pain. Here in this essay, we aim to discuss important aspects of cardiac failure in relation to abnormal sympatho-activators through evaluation of different available studies and animal models.


2017 ◽  
Vol 1 (3) ◽  
pp. 01-02
Author(s):  
David Bell

From the UKPDS it was concluded that metformin decreased cardiac events. However, this only occurred in a small group of obese subjects while in a larger group failing sulfonylurea therapy the addition of metformin resulted in an increase in cardiac events . Indeed, a meta-analysis of metformin studies has shown that overall metformin does not decrease cardiac events. However, if in this meta-analysis the group utilizing metformin and sulfonylurea combinations were removed from the analysis then there was a significant decrease in cardiac events with metformin monotherapy. The major decrease in cardiac events, cardiac mortality and total mortality with metformin is likely due to a decreased susceptibility to develop heart failure. From Medicare billing records of 16,417 diabetic patients with heart failure discharged from hospital on metformin were compared to those with heart failure discharged on a sulfonylurea or insulin, mortality was reduced by 13% and readmission by 8%.


2017 ◽  
Vol 113 (10) ◽  
pp. 1148-1160 ◽  
Author(s):  
Desiree Abdurrachim ◽  
Miranda Nabben ◽  
Verena Hoerr ◽  
Michael T. Kuhlmann ◽  
Philipp Bovenkamp ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document